NGVT Stock Recent News
NGVT LATEST HEADLINES
The headline numbers for Ingevity (NGVT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ingevity (NGVT) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to earnings of $0.57 per share a year ago.
Ingevity (NGVT) reported earnings 30 days ago. What's next for the stock?
TRiiSO's technical support strengths complement Ingevity's (NGVT) commitment to providing solutions to challenging formulation issues.
Ingevity Corporation (NYSE:NGVT ) Q3 2023 Earnings Conference Call November 2, 2023 10:00 AM ET Company Participants John Nypaver - VP of IR & Treasurer John Fortson - President, CEO & Director Mary Hall - EVP & CFO Richard White - SVP & President, Performance Chemicals Stuart Woodcock - EVP & President, Performance Materials Conference Call Participants Vincent Anderson - Stifel, Nicolaus & Company Jonathan Tanwanteng - CJS Securities John McNulty - BMO Capital Markets Daniel Rizzo - Jefferies Christopher Kapsch - Loop Capital Markets Operator Good morning or good afternoon, and welcome to the Ingevity Third Quarter 2023 Earnings Call and Webcast. My name is Adam, and I'll be your operator for today.
Lower volumes due to weak industrial demand hurt Ingevity's (NGVT) Advanced Polymer Technologies and the Industrial Specialties business lines in Q3.
While the top- and bottom-line numbers for Ingevity (NGVT) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
NORTH CHARLESTON, S.C.--(BUSINESS WIRE)--Ingevity announced today that it will release its third-quarter 2023 earnings after the stock market close on Wednesday, November 1, 2023.
Ingevity Corporation has seen declines in price due to recent earnings and balance sheet risks. Despite the leveraged balance sheet, Ingevity's diversification strategy and undervaluation make it a favorable investment. Analysts rate Ingevity as a "buy" with a 55.89% upside potential, indicating a positive risk-reward ratio.
Ingevity (NGVT) reported earnings 30 days ago. What's next for the stock?